The US District Court for the Eastern District of Virginia has invalidated one of Pfizer’s patents covering blockbuster arthritis drug Celebrex.
Genetic diagnostic company Myriad Genetics and other patent holders have been denied a motion for a preliminary injunction that would have kept rival company Ambry Genetics from selling its own test for BRCA gene mutations.
Texas-based biopharmaceutical company Caisson Biotech has expanded its partnership with diabetes therapy maker Novo Nordisk by giving Novo exclusive rights to commercialise an insulin treatment that uses Caisson’s drug delivery technology.
The Unified Patent Court has clarified its opt-out scheme, making clear that when a European patent has been opted out of the scheme, its associated supplementary protection certificate will follow.
While the political will exists for the introduction of the Unified Patent Court next year, much more still needs to be done, according to Adam Cooke, a partner in DLA Piper's IP and technology group.
A key concern for lawyers and in-house counsels practising in the pharmaceutical industry is the disclosure of clinical data, according to the co-chairs of DLA Piper's Global Life Sciences sector, Bonella Ramsay and John Dougherty.
The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate).
The US Appeals Court for the Federal Circuit has affirmed a lower court decision that GlaxoSmithKline’s patent covering Avodart and Jalyn is valid, rejecting claims put forward by a group of generic drug makers.
Bayer has announced that it plans to acquire Dihon Pharmaceutical Group, a Chinese company that makes over-the-counter (OTC) and herbal traditional Chinese medicine (TCM) products.
The US District Court for the District of Maryland has ruled that Taiwanese company TWi Pharmaceuticals’ generic version of Par Pharmaceuticals’ Megace ES drug does not infringe US patent 7,101,576.